SEC Form 4 · accession 0001209191-18-036995
AMICUS THERAPEUTICS, INC. · FOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ted W Love
Director
Period of report
Jun 7, 2018
Accepted (ET)
Jun 11, 2018 · 4:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178879
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 7, 2018 | A | 3,081 | $0.00 | A | 8,895 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F2 | $16.23 | Jun 7, 2018 | A | 8,912 | A | — | Jun 7, 2028 | Common Stock | 8,912 | 8,912 | D |
Explanation of responses
- F1The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common stock.
- F2One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2019.